184 related articles for article (PubMed ID: 23579952)
1. Connexin 26 is down-regulated by KDM5B in the progression of bladder cancer.
Li X; Su Y; Pan J; Zhou Z; Song B; Xiong E; Chen Z
Int J Mol Sci; 2013 Apr; 14(4):7866-79. PubMed ID: 23579952
[TBL] [Abstract][Full Text] [Related]
2. Original Research: miR-194 inhibits proliferation and invasion and promotes apoptosis by targeting KDM5B in esophageal squamous cell carcinoma cells.
Cui G; Liu D; Li W; Li Y; Liang Y; Shi W; Zhao S
Exp Biol Med (Maywood); 2017 Jan; 242(1):45-52. PubMed ID: 27480251
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway.
Hayami S; Yoshimatsu M; Veerakumarasivam A; Unoki M; Iwai Y; Tsunoda T; Field HI; Kelly JD; Neal DE; Yamaue H; Ponder BA; Nakamura Y; Hamamoto R
Mol Cancer; 2010 Mar; 9():59. PubMed ID: 20226085
[TBL] [Abstract][Full Text] [Related]
4. Overexpressed KDM5B is associated with the progression of glioma and promotes glioma cell growth via downregulating p21.
Dai B; Hu Z; Huang H; Zhu G; Xiao Z; Wan W; Zhang P; Jia W; Zhang L
Biochem Biophys Res Commun; 2014 Nov; 454(1):221-7. PubMed ID: 25450384
[TBL] [Abstract][Full Text] [Related]
5. Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448.
Bamodu OA; Huang WC; Lee WH; Wu A; Wang LS; Hsiao M; Yeh CT; Chao TY
BMC Cancer; 2016 Feb; 16():160. PubMed ID: 26917489
[TBL] [Abstract][Full Text] [Related]
6. The histone-H3K4-specific demethylase KDM5B binds to its substrate and product through distinct PHD fingers.
Klein BJ; Piao L; Xi Y; Rincon-Arano H; Rothbart SB; Peng D; Wen H; Larson C; Zhang X; Zheng X; Cortazar MA; Peña PV; Mangan A; Bentley DL; Strahl BD; Groudine M; Li W; Shi X; Kutateladze TG
Cell Rep; 2014 Jan; 6(2):325-35. PubMed ID: 24412361
[TBL] [Abstract][Full Text] [Related]
7. Investigation of the potential theranostic role of KDM5B/miR-29c signaling axis in paclitaxel resistant endometrial carcinoma.
Li L; Shou H; Wang Q; Liu S
Gene; 2019 Apr; 694():76-82. PubMed ID: 30658067
[TBL] [Abstract][Full Text] [Related]
8. Depletion of histone demethylase KDM5B inhibits cell proliferation of hepatocellular carcinoma by regulation of cell cycle checkpoint proteins p15 and p27.
Wang D; Han S; Peng R; Jiao C; Wang X; Yang X; Yang R; Li X
J Exp Clin Cancer Res; 2016 Feb; 35():37. PubMed ID: 26911146
[TBL] [Abstract][Full Text] [Related]
9. Histone lysine demethylase KDM5B maintains chronic myeloid leukemia via multiple epigenetic actions.
Xue S; Lam YM; He Z; Zheng Y; Li L; Zhang Y; Li C; Mbadhi MN; Zheng L; Cheng Z; Liu Y; Wang X; Chan LC; Ng RK; Zhang J
Exp Hematol; 2020 Feb; 82():53-65. PubMed ID: 32007477
[TBL] [Abstract][Full Text] [Related]
10. Lysine demethylase 5B suppresses CC chemokine ligand 14 to promote progression of colorectal cancer through the Wnt/β-catenin pathway.
Yan G; Li S; Yue M; Li C; Kang Z
Life Sci; 2021 Jan; 264():118726. PubMed ID: 33160990
[TBL] [Abstract][Full Text] [Related]
11. Increased Expression of Lysine-Specific Demethylase 5B (KDM5B) Promotes Tumor Cell Growth in Hep3B Cells and is an Independent Prognostic Factor in Patients with Hepatocellular Carcinoma.
Gong J; Yan S; Yu H; Zhang W; Zhang D
Med Sci Monit; 2018 Oct; 24():7586-7594. PubMed ID: 30353907
[TBL] [Abstract][Full Text] [Related]
12. KDM5B demethylates H3K4 to recruit XRCC1 and promote chemoresistance.
Xu W; Zhou B; Zhao X; Zhu L; Xu J; Jiang Z; Chen D; Wei Q; Han M; Feng L; Wang S; Wang X; Zhou J; Jin H
Int J Biol Sci; 2018; 14(9):1122-1132. PubMed ID: 29989047
[TBL] [Abstract][Full Text] [Related]
13. Histone lysine demethylase KDM5B facilitates proliferation and suppresses apoptosis in human acute myeloid leukemia cells through the miR-140-3p/BCL2 axis.
Huang J; Jin S; Guo R; Wu W; Yang C; Qin Y; Chen Q; He X; Qu J; Yang Z
RNA; 2024 Mar; 30(4):435-447. PubMed ID: 38296629
[TBL] [Abstract][Full Text] [Related]
14. Histone demethylase lysine demethylase 5B in development and cancer.
Han M; Xu W; Cheng P; Jin H; Wang X
Oncotarget; 2017 Jan; 8(5):8980-8991. PubMed ID: 27974677
[TBL] [Abstract][Full Text] [Related]
15. SUMOylation negatively modulates target gene occupancy of the KDM5B, a histone lysine demethylase.
Bueno MT; Richard S
Epigenetics; 2013 Nov; 8(11):1162-75. PubMed ID: 23970103
[TBL] [Abstract][Full Text] [Related]
16. Histone demethylase KDM5B collaborates with TFAP2C and Myc to repress the cell cycle inhibitor p21(cip) (CDKN1A).
Wong PP; Miranda F; Chan KV; Berlato C; Hurst HC; Scibetta AG
Mol Cell Biol; 2012 May; 32(9):1633-44. PubMed ID: 22371483
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylation of the histone demethylase KDM5B and regulation of the phenotype of triple negative breast cancer.
Yeh IJ; Esakov E; Lathia JD; Miyagi M; Reizes O; Montano MM
Sci Rep; 2019 Nov; 9(1):17663. PubMed ID: 31776402
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the histone demethylase, KDM5B, directly induces re-expression of tumor suppressor protein HEXIM1 in cancer cells.
Montano MM; Yeh IJ; Chen Y; Hernandez C; Kiselar JG; de la Fuente M; Lawes AM; Nieman MT; Kiser PD; Jacobberger J; Exner AA; Lawes MC
Breast Cancer Res; 2019 Dec; 21(1):138. PubMed ID: 31805991
[TBL] [Abstract][Full Text] [Related]
19. The PHD1 finger of KDM5B recognizes unmodified H3K4 during the demethylation of histone H3K4me2/3 by KDM5B.
Zhang Y; Yang H; Guo X; Rong N; Song Y; Xu Y; Lan W; Zhang X; Liu M; Xu Y; Cao C
Protein Cell; 2014 Nov; 5(11):837-50. PubMed ID: 24952722
[TBL] [Abstract][Full Text] [Related]
20. Novel KDM5B splice variants identified in patients with developmental disorders: Functional consequences.
Lebrun N; Mehler-Jacob C; Poirier K; Zordan C; Lacombe D; Carion N; Billuart P; Bienvenu T
Gene; 2018 Dec; 679():305-313. PubMed ID: 30217758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
